AC Immune SA (ACIU)
|Net Income (ttm)||-70.36M|
|Trading Day||July 26|
|Day's Range||7.30 - 7.56|
|52-Week Range||4.42 - 12.50|
LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...
AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile
AC Immune SA (NASDAQ: ACIU) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No sa...
AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates
AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor Conferences
LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announ...
AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatme...
AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today repo...
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
Dr. Colowick has more than 20 years of experience in large and emerging biotech companies
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for N...
Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics Clinically validated platform accelerates the...
Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases
Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to ($0.28), wh...
LAUSANNE, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today repo...
Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurod...
Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43
Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.
Swiss biopharma AC Immune has released positive updates this week on both its Alzheimer's and Parkinson's disease treatments. Investors are piling in to ACIU stock.
AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-...
Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's disease
LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...
Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylate...
Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital
Prof. June is a world authority on immune tolerance and adoptive immunotherapy
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
Prof. Streffer is a n established authority on n euroscience and b iomarker modalities
AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate...
LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune's Anti-TDP-43 Antibodies into C...
Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.
Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic...
Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
AC Immune S.A. (NASDAQ: ACIU) stock was absolutely crushed on Wednesday after one of the firm’s partners announced disappointing results from its midstage Alzheimer’s disease study.
Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug.
AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met
AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference
LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseas...
Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
First-in-class TDP-43 antibody developed using SurpraAntigen™ platform
AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results present...
Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio
AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association ...
Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases Presentations to highlight the Company’s broad expertise address...
AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.
Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company.
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study
Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy
Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph... [Read more...]
|IPO Date |
Sep 23, 2016
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for AC Immune stock is "Buy." The 12-month stock price forecast is 13.99, which is an increase of 85.54% from the latest price.